• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Norway·Healthcare·HBC.OL
Share

Hofseth BioCare ASA Stocks

NOK 1.52Last Updated 09.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NOK 57.08M

NOK 1.52
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hofseth BioCare ASA, an international firm based in Norway, specializes in developing and supplying premium biomarine ingredients for both human and animal health. The company's product portfolio features various specialized offerings, including Brilliant salmon oil and OmeGo salmon oil, which promotes healthy cholesterol levels and supports cardiovascular well-being. ProGo, a salmon protein hydrolysate, serves as a rapidly assimilated protein supplement. For skeletal and joint health, Hofseth offers CalGo, a marine calcium powder. CollaGo, a collagen peptide powder, is designed to improve the appearance of hair, skin, and nails. Additionally, PetGo provides a non-soluble protein formulation. Distribution of these products is managed through a multi-channel approach, utilizing a network of distributors, agents, and its dedicated internal sales team. Hofseth BioCare also holds a significant research collaboration with Stanford University School of Medicine, focusing on pre-clinical and clinical studies related to conditions such as necrotizing enterocolitis and irritable bowel syndrome. Established in 2000, the company's main operations are based in Ålesund, Norway.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.07.2026 23:06

Delta's profits were eaten up by record fuel costs. But revenue was buoyed by demand

10.07.2026 21:56

An Unwelcome Measure: Why Kazakhstan Is Abolishing the Mandatory Sale of Foreign Currency Proceeds

10.07.2026 20:51

SK Hynix shares rose 14% to $170 at the start of trading on their debut

10.07.2026 20:07

Trump announced that negotiations with Iran would continue. But he added: “The truce is over.”

10.07.2026 19:45

Plenty of Oil, but No Gasoline: The IEA Warned That Consumption Will Fall for the First Time Since 2020

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026